NCT06141265View on ClinicalTrials.gov

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions
DRUG

Niraparib

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER